Clinical Trials Logo

Clinical Trial Summary

This study aims to define the pharmacokinetic (PK) properties of a commonly used antibiotic to treat cIAI, metronidazole, in the intestinal wall tissue of healthy infants undergoing intestinal surgery to optimize intestinal wall penetration of antibiotics in infants. Metronidazole will be given at standard of care intravenous loading dose of 30 mg/kg 15 minutes prior to incision, with a maximum dose of 2g. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision, and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than 5mL total.


Clinical Trial Description

This is a single center pilot pharmacokinetic (PK) study to concomitantly measure antibiotic concentrations in the plasma and the intestinal wall of healthy infants undergoing intestinal surgery. Metronidazole will be given at standard of care intravenous loading dose of 30 mg/kg 15 minutes prior to incision, with a maximum dose of 2g. Exact time, dose, and infusion rate and duration will be recorded. The use of a loading dose will allow characterization of plasma and tissue PK after a single dose that would be expected with steady state dosing, thus increasing the translatability of the investigator's findings to cIAI treatment. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision, and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than 5mL total. At the time of intestinal excision, the surgeon will cut at least 250mg of intestine from the specimen, ensuring all layers of bowel are included. This sample will be placed in a sterile, dry container. All samples will be processed and stored in a -80°C freezer within 1 hour of acquisition. Samples will be batched and shipped to a central commercial laboratory (OpAns Analytical Solutions LLC, Durham, NC) for concentration measurement of metronidazole and its primary metabolite 2-hydroxymetronidazole using a HPLC/MS/MS plasma assay previously developed and validated per FDA guidance. This assay will be modified and validated for tissue concentration measurement utilizing porcine intestinal tissue and run over three mediums to ensure correct measurement. The samples will also be used to quantify CYP2A6 protein levels using commercially available enzyme-linked immunosorbent assay kits. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04299867
Study type Observational
Source Duke University
Contact
Status Completed
Phase
Start date July 15, 2020
Completion date April 25, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04205058 - Coffee After Pancreatic Surgery N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A
Completed NCT00135577 - Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects Phase 2
Completed NCT03028636 - LIBERATE - PRO: Eclipseâ„¢ System Registry
Completed NCT05880446 - PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) N/A
Active, not recruiting NCT06311110 - Impaired Toilet Training, LUTS and Bowel Dysfunction in Children With DCD
Not yet recruiting NCT04507945 - Stablishment of Prevention and Treatment System for Intestinal Dysfunction Phase 1/Phase 2
Completed NCT00101998 - Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication Phase 2
Recruiting NCT05716230 - Bowel Function and Associated Risk Factors for Bowel Dysfunciton in Patients With Anorectal Malformation
Completed NCT05644912 - Exploratory Investigation on a Novel Catheter N/A
Recruiting NCT04319991 - The Clinical Evaluation of Probiotics Product in Patients With Various Functional Bowel Disorders and Helicobacter Pylori Infection N/A
Completed NCT03885999 - Studies in Patients With Low Anterior Resection Syndrome (LARS) N/A
Active, not recruiting NCT04546672 - Sugammadex To IMprove Bowel Function Phase 4
Not yet recruiting NCT06252714 - Impact of Defecation Posture on Ease of Bowel Movements in Patients With a Rectocele N/A
Recruiting NCT04914975 - The Effect of NMES on Bowel Management in People With Chronic SCI N/A
Active, not recruiting NCT04490642 - Linguistic Validation of the Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ) for 5-12 Years Old in Korean
Recruiting NCT06288464 - Enteral Feeding of Fibre to Improve Microbiota N/A
Completed NCT05351138 - Comparison of Transcutaneous Electrical Nerve Stimulation and Manual Therapy in Children With Cerebral Palsy N/A
Completed NCT03841513 - Minimally Invasive Burch Colposuspension to Reduce Occult Stress Incontinence N/A
Not yet recruiting NCT03009747 - A Prospective Multi-Center Research on Bowel Dysfunction After Sphincter Preservative Surgery N/A